Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

| Create an account https://orcid.org

Search life-sciences literature (45,103,589 articles, preprints and more)

Suggested authors matching "AUTH:Pignata S" with an ORCID

Silvia Pignata
University of South Australia
6
Publications
96
Citations
View profile

Search results

1-25 of 480 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe.
Moore KN, Mirza MR, Gourley C, Pignata S, Lorusso D, Monk BJ, Sehouli J, Schilder JM, D'Esquermes N, González-Martín A
Int J Gynecol Cancer, 34(11):1753-1760, 04 Nov 2024
Cited by: 0 articles | PMID: 39164040
Add to export list
Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial.
Indraccolo S, Signoriello S, Piga I, Esposito G, Ferrarini F, Boscolo Bragadin A, Salutari V, Pisano C, Califano D, Bignotti E, Tognon G, Simeon V, Artioli G, Ferrero A, Cinieri S, Bologna A, Chiodini P, Scognamiglio G, Bottoni C, [...] Pignata S
Int J Biol Markers, 3936155241296164, 08 Nov 2024
Cited by: 0 articles | PMID: 39513196
Add to export list
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.
Bignotti E, Simeon V, Ardighieri L, Kuhn E, Marchini S, Califano D, Cecere SC, Bugatti M, Spina A, Scognamiglio G, Paracchini L, Russo D, Arenare L, Tognon G, Lorusso D, Beltrame L, D'Incalci M, Sartori E, De Censi A, [...] Pignata S
Int J Cancer, 16 Oct 2024
Cited by: 0 articles | PMID: 39415516
Add to export list
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer.
Perez-Fidalgo A, Schmalfeldt B, George A, Gourley C, Pignata S, Lorusso D, Barretina-Ginesta MP, Romero I, Grimm C, Van Gorp T, Rossing M, Collins DC, Fernebro J, Bjørge L, Leary A, de la Motte Rouge T, Harter P, Kurzeder C, Savva-Bordalo J, You B
Int J Gynecol Cancer, ijgc-2024-005497, 23 Oct 2024
Cited by: 0 articles | PMID: 39448084
Add to export list
Endometrial cancer in the elderly: Characteristics, prognostic and risk factors, and treatment options.
Forte M, Cecere SC, Di Napoli M, Ventriglia J, Tambaro R, Rossetti S, Passarelli A, Casartelli C, Rauso M, Alberico G, Mignogna C, Fiore F, Setola SV, Troiani T, Pignata S, Pisano C
Crit Rev Oncol Hematol, 204:104533, 22 Oct 2024
Cited by: 0 articles | PMID: 39442900
Add to export list Review
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.
Haggstrom L, Lee YC, Scott C, Harter P, Woelber L, Ledermann J, Gourley C, McNeish IA, Amant F, Ray-Coquard I, Leary A, Oza AM, Tinker A, González Martin A, Cecere SC, Pignata S, Colombo N, Yoshida H, Marth C, [...] Friedlander ML
Int J Gynecol Cancer, ijgc-2024-005976, 22 Oct 2024
Cited by: 0 articles | PMID: 39438068
Add to export list
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study.
Patrikidou A, Saieva C, Lee-Ying R, Nuzzo PV, Zarif TE, McClure H, Davidsohn M, Eid M, Spinelli GP, Catalano F, Cremante M, Fotia G, Rossetti S, Valenca L, Vauchier C, Ottanelli C, Andrade L, Gennusa V, Mestre RP, [...] SPARTACUSS Group
Clin Genitourin Cancer, 22(6):102230, 05 Oct 2024
Cited by: 0 articles | PMID: 39461026
Add to export list
KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.
Santagata S, Trotta AM, D'Alterio C, Napolitano M, Rea G, Di Napoli M, Portella L, Ieranò C, Guardascione G, Coppola E, Caux C, Dubois B, Boyle HJ, Carles J, Rossetti S, Azzaro R, Feroce F, Perdonà S, Fordellone M, [...] Scala S
Clin Cancer Res, 30(20):4755-4767, 01 Oct 2024
Cited by: 0 articles | PMID: 39167621 | PMCID: PMC11474171
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Stereotactic Ablative Radiation Therapy for Oligometastatic Ovarian Cancer Lymph Node Disease: The MITO-RT3/RAD Phase II Trial.
Macchia G, Campitelli M, Pezzulla D, Lucci S, Fodor A, Russo D, Balcet V, Bonome P, Durante S, Draghini L, Titone F, D'Agostino GR, Tamburo M, Ferioli M, Ippolito E, Tortoreto F, Caravatta L, De Felice F, Stefano AD, [...] Deodato F
Int J Radiat Oncol Biol Phys, S0360-3016(24)03402-3, 24 Sep 2024
Cited by: 0 articles | PMID: 39326506
Add to export list
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Cvek J, Randall L, Pereira de Santana Gomes AJ, Contreras Mejía F, Helpman L, Akıllı H, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, [...] ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators
Lancet, 404(10460):1321-1332, 14 Sep 2024
Cited by: 1 article | PMID: 39288779
Add to export list
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type.
Buonaiuto R, Neola G, Caltavituro A, Longobardi A, Mangiacotti FP, Cefaliello A, Lamia MR, Pepe F, Ventriglia J, Malapelle U, Troncone G, Giuliano M, Arpino G, Pignata S, De Angelis C
Front Oncol, 14:1412807, 09 Sep 2024
Cited by: 0 articles | PMID: 39314634 | PMCID: PMC11416912
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study.
Fotia G, Saieva C, Lee-Ying R, Patrikidou A, Nuzzo PV, Zanardi E, Rossetti S, Davidsohn M, Eid M, El Zarif T, McClure H, Spinelli GP, Damassi A, Murianni V, Vauchier C, Oliveira TM, Malgeri A, Modesti M, Mestre RP, [...] Spartacuss Group
Clin Genitourin Cancer, 22(5):102185, 09 Aug 2024
Cited by: 0 articles | PMID: 39217072
Add to export list
CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterization.
Portella L, Bertolini G, Guardascione G, Di Febbraro DG, Ieranò C, D'Alterio C, Rea G, Napolitano M, Santagata S, Trotta AM, Camerlingo R, Scarpa E, Cecere SC, Ottaiano A, Palumbo G, Morabito A, Somma T, De Rosa G, Mayol L, [...] Scala S
Heliyon, 10(15):e35524, 31 Jul 2024
Cited by: 0 articles | PMID: 39170328 | PMCID: PMC11336720
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study).
Rebuzzi SE, Fornarini G, Signori A, Buti S, Procopio G, De Giorgi U, Pignata S, Naglieri E, Maruzzo M, Banna GL, Rescigno P, Messina C, Mattana A, Basso U, Bimbatti D
BMC Cancer, 24(1):757, 24 Jun 2024
Cited by: 4 articles | PMID: 38914928 | PMCID: PMC11194925
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Lymphomas of the Vulva: A Review of the MITO Rare Cancer Group.
Magazzino F, Aristei C, Passarelli A, Pierini A, De Giorgi U, Martinello R, Domenici L, Pignata S, Mangili G, Cormio G
Cancers (Basel), 16(11):2102, 31 May 2024
Cited by: 0 articles | PMID: 38893221 | PMCID: PMC11171216
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
Roma C, Esposito Abate R, Sacco A, Califano D, Arenare L, Bergantino F, Pisano C, Cecere SC, Scambia G, Lorusso D, Artioli G, Tasca G, Spina A, Russo D, Gadducci A, De Angelis C, Bologna A, Marchini S, Capoluongo ED, [...] Normanno N
Eur J Cancer, 206:114127, 23 May 2024
Cited by: 0 articles | PMID: 38797038
Add to export list
Venous Thromboembolism Prophylaxis in Gynecologic Oncology: A MITO-MaNGO Survey.
Mongelli M, Lorusso D, Zanagnolo V, Pignata S, Colombo N, Cormio G
Diagnostics (Basel), 14(11):1159, 31 May 2024
Cited by: 0 articles | PMID: 38893685 | PMCID: PMC11172117
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways.
Pastò B, Buzzatti G, Schettino C, Malapelle U, Bergamini A, De Angelis C, Musacchio L, Dieci MV, Kuhn E, Lambertini M, Passarelli A, Toss A, Farolfi A, Roncato R, Capoluongo E, Vida R, Pignata S, Callari M, Baldassarre G, [...] Puglisi F
Crit Rev Oncol Hematol, 199:104379, 07 May 2024
Cited by: 0 articles | PMID: 38718940
Add to export list Review
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.
Pignata S, Califano D, Lorusso D, Arenare L, Bartoletti M, De Giorgi U, Andreetta C, Pisano C, Scambia G, Lombardi D, Farolfi A, Cinieri S, Passarelli A, Salutari V, De Angelis C, Mignogna C, Priolo D, Capoluongo ED, Tamberi S, [...] Perrone F
Ann Oncol, 35(7):667-676, 03 May 2024
Cited by: 2 articles | PMID: 38704093
Add to export list
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients.
Santagata S, Rea G, Bello AM, Capiluongo A, Napolitano M, Desicato S, Fragale A, D'Alterio C, Trotta AM, Ieranò C, Portella L, Persico F, Di Napoli M, Di Maro S, Feroce F, Azzaro R, Gabriele L, Longo N, Pignata S, [...] Scala S
Br J Cancer, 130(12):2016-2026, 04 May 2024
Cited by: 1 article | PMID: 38704478 | PMCID: PMC11183124
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
Tuninetti V, Virano E, Salutari V, Ricotti A, Pisano C, Ducceschi M, Turitto G, Scandurra G, Petrella MC, Forestieri V, Rizzetto M, Mammoliti S, Artioli G, Cioffi R, Borsotti L, Bellero M, Rognone C, Carbone V, Ferrandina G, [...] Valabrega G
Eur J Cancer, 203:114039, 30 Mar 2024
Cited by: 0 articles | PMID: 38598922
Add to export list
Aggressive Angiomyxoma of the Lower Female Genital Tract: A Review of the MITO Rare Tumors Group.
Dellino M, Magazzino F, Domenici L, Cicogna S, Miano ST, Pignata S, Mangili G, Cormio G
Cancers (Basel), 16(7):1375, 31 Mar 2024
Cited by: 0 articles | PMID: 38611053 | PMCID: PMC11011140
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, Pereira de Santana Gomes AJ, Contreras Mejía F, Reiss A, Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, [...] ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators
Lancet, 403(10434):1341-1350, 20 Mar 2024
Cited by: 25 articles | PMID: 38521086
Add to export list
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, [...] KEYNOTE-564 Investigators
N Engl J Med, 390(15):1359-1371, 01 Apr 2024
Cited by: 14 articles | PMID: 38631003
Add to export list
Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials.
Arenare L, Di Liello R, De Placido P, Gridelli C, Morabito A, Pignata S, Nuzzo F, Avallone A, Maiello E, Gargiulo P, Schettino C, Gravina A, Gallo C, Chiodini P, Di Maio M, Perrone F, Piccirillo MC
ESMO Open, 9(3):102941, 06 Mar 2024
Cited by: 0 articles | PMID: 38452437
Add to export list

1-25 of 480 results

1 2 3 Next ...

Search life-sciences literature (45,103,589 articles, preprints and more)

Suggested authors matching "AUTH:Pignata S" with an ORCID Suggested authors have linked their articles in Europe PMC to their ORCID iD. Up to two suggested authors with a matching surname and initial are shown, ordered by the total number of publications they have in Europe PMC.

Search results

Partnerships & funding

Suggested authors matching "AUTH:Pignata S" with an ORCID